This PubMed record describes a multicenter study published in Eur J Cancer under the title “Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.” The article is listed as a free article with PubMed PMID 42349343 and DOI 10.1016/j.ejca.2026.116902. Publication metadata include electronic publication on 21 June 2026 and journal issue citation 2026 Aug 26:244:116902.
The publication lists a large collaborative author group led by Kinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama and many additional coauthors. Affiliations span multiple institutions in Japan, primarily departments of Respiratory Medicine, Clinical Immunology, and Thoracic Oncology across universities and regional medical centers in Osaka and Hyogo prefectures. The PubMed entry enumerates institutional affiliations for each contributing author, reflecting a multicenter collaboration among university hospitals, national hospital organizations, municipal hospitals, and cancer institutes.
The article is identified as a “Multicenter Study” in the PubMed record. The title indicates the study evaluated the impact of preexisting interstitial lung disease on two principal outcomes during first-line immune checkpoint inhibitor-based therapy for non-small cell lung cancer: the occurrence of pneumonitis and patient survival. Beyond the study type label and the focus stated in the title, the PubMed source content available here does not provide additional internal details regarding sample size, eligibility criteria, specific ICI regimens, follow-up duration, or analytic methods.
According to the article title, the central research question addresses whether and how existing interstitial lung disease influences (1) the risk or incidence of pneumonitis and (2) survival outcomes among patients with NSCLC receiving first-line ICI-based therapy. The title identifies these key variables—preexisting interstitial lung disease, pneumonitis, survival, first-line therapy, immune checkpoint inhibitor-based regimens, and non-small cell lung cancer—but the PubMed record excerpt provided does not include the abstract text or study findings that would specify results, effect sizes, or statistical significance.
The PubMed page shows the entry is a free article and provides links to full-text options, including a link to Elsevier Science (linking hub) for full-text retrieval. Users seeking the complete study report, including methods, results, tables, and authors’ conclusions, should follow the full-text links from the PubMed entry or obtain the article through institutional access or the journal’s website. The PubMed record itself includes comprehensive author and affiliation details and the DOI for direct journal lookup.
The version of the PubMed record provided here does not include the abstract, methods, results, or conclusions. Specifics not reported in this source content include, but are not limited to:
To obtain these missing details, consult the full-text article via the DOI (10.1016/j.ejca.2026.116902) or the Elsevier linking hub provided on the PubMed page. Institutional library resources or the journal’s website will provide the complete manuscript and supplementary material if available.
The article title identifies a clinically important topic: how preexisting interstitial lung disease may affect the safety (pneumonitis risk) and efficacy (survival) of first-line immune checkpoint inhibitor-based therapy in NSCLC. This question is relevant to clinicians managing NSCLC patients with baseline lung comorbidity who are being considered for ICI-containing regimens. However, because the abstract and study results are not present in the provided PubMed content, no conclusions about observed risk magnitudes, management implications, or practice-changing findings can be drawn from this record alone. Readers should review the full published study for evidence-based data and the authors’ conclusions before applying findings to clinical care.
Note: The content above strictly reflects bibliographic and title-based information available in the provided PubMed record. Study methodology, numeric results, and conclusions were not reported in the source excerpt and therefore are not summarized here. For full details, retrieve the complete article via the DOI or journal links shown on PubMed.